Market Signal Briefing

After a turbulent few days, Bitcoin (BTC) has resumed its downtrend, currently retracing toward $111,000. This marks a 12% decline from its recent peak of $126,000, which raises concerns among market experts who suggest that the bull run may be closer to its end than many investors believe.

End Of Bitcoin Bull Cycle Within Nine Days?
On October 14, market analyst CryptoBirb, took to social media platform X (formerly Twitter) to assert that the bullish cycle is nearing its conclusion, stating that it may end within the next nine days. 

He referenced the Cycle Peak Countdown indicator, which suggests that Bitcoin is 99.3% through its current cycle, having lasted 1,058 days. According to CryptoBirb, this final stage is characterized by a “textbook shakeout of weak hands,” a common pattern observed before market peaks. 

CryptoBirb emphasized that October 24 serves as a critical target date, just nine days away, and labeled the recent crash as “right on schedule.” He further explained that the market is deep within the peak zone, with 543 days elapsing since the last Bitcoin Halving, exceeding the historical peak window of 518 to 580 days. 

Bitcoin price performance after its Halving. Source: CryptoBirb on X
The sentiment in the market also appears to have shifted dramatically, with the Fear & Greed Index plummeting from 71 to 38, indicating a reset from fear to euphoria. The Relative Strength Index (RSI) also dropped from 67 to 47, suggesting that this emotional washout may create an ideal launchpad for a final euphoric surge. 

However, technical indicators show mixed signals: while the Average True Range (ATR) has expanded to 4,040, indicating higher volatility, the RSI’s position at 47 suggests a reset momentum. 

What On-Chain Metrics Suggest
Institutional investors have also begun to shift their strategies, as evidenced by recent Bitcoin Exchange-Traded Fund (ETF) flows, which reversed from $627 million in inflows to $4.5 million in outflows. 

Ethereum ETF outflows reached $174.9 million, indicating that smart money is taking profits before retail investors potentially fear of missing out (FOMO) in. CryptoBirb asserts that this behavior aligns with a classic distribution-to-accumulation transition.

On-chain metrics reflect a cooling market, with the Net Unrealized Profit/Loss (NUPL) dropping to 0.522 from 0.556, and the Market Value to Realized Value (MVRV) declining to 2.15 from 2.45. These profit-taking actions may be creating the necessary space for a final euphoric push. 

When examining October’s performance, Bitcoin is down 2.09% month-to-date, contrasting sharply with its historical average of a 19.78% increase. This underperformance could actually be a bullish sign, suggesting that a significant move may still be on the horizon in the final weeks of the month.

In summary, the current cycle appears to be 99.3% complete. It has already spent 25 days in the peak zone and experienced a reset in sentiment and institutional distribution, as well as weak performance in October. However, if the analyst’s thesis proves right, this blending could turn into a perfect storm for a final surge before entering a new crypto winter. 

The daily chart shows BTC’s increased volatility met with major price swings. Source: BTCUSDT on TradingView.com
Featured image from DALL-E, chart from TradingView.com 

XRP trades near $2.5 after a sharp weekly decline as traders await exchange-traded fund decisions and Ripple’s inks a new partnership with Absa Bank.

Summary

XRP price is down 15% weekly, having retraced 33% from July ATH.
SEC ETF decisions and Ripple’s Absa Bank deal drive positive sentiment.
Key support is at $2.30; reclaiming $2.75 could spark rebound.

XRP was trading at $2.42 at press time, down 3.6% over the last day and 15% over the last week. The token has retraced about 33% from its peak of $3.65 in July. Over the past week, it has moved within a range of $2.32–$2.83 as traders brace for major catalysts.

The 24-hour trading volume has decreased by 27% to $5.1 billion. According to CoinGlass data, open interest fell 2.2% to $4.04 billion and derivatives volume decreased 36.5% to $6.56 billion, indicating declining leverage and a short-term pause in speculative momentum.

XRP ETF deadlines boost sentiment
The coming days could define XRP’s (XRP) price direction. Between Oct. 18–25, the U.S. Securities and Exchange Commission faces clustered deadlines for several spot XRP ETF applications, including Grayscale, 21Shares, Bitwise, Canary, WisdomTree, and CoinShares, with Franklin Templeton’s review extended to Nov. 14.

The Rex-Osprey XRPR ETF, launched on Sept. 18, logged $37.7 million in first-day volume on Cboe, showing strong investor demand. With Ripple’s clear regulatory standing following its 2025 court victory, analysts predict that there will be at least one approval by year’s end.

However, the precise timeline is uncertain due to the SEC’s workflow being slowed by a partial U.S. government shutdown that began on Oct. 1.

Ripple’s Africa expansion with Absa Bank
Announced on Oct. 15, Ripple’s new partnership with Absa Bank represents its first significant custody client in Africa. Absa, which oversees $119 billion in assets in 12 African nations, will use Ripple’s self-custodial platform to securely store digital assets and Ripple’s RLUSD stablecoin. 

Today, we’re excited to announce that @AbsaSouthAfrica, one of Africa’s leading financial institutions, is now @Ripple’s first major custody partner in Africa: https://t.co/9FQ5GTxMnK

We’re bringing institutional digital asset custody to South Africa, providing the secure and…

— Ripple (@Ripple) October 15, 2025

The partnership extends Ripple’s network to five continents and improves institutional access to tokenized assets and On-Demand Liquidity.

XRP price technical analysis
The technical structure of XRP points to a cautious phase. The price has confirmed short-term bearish pressure by falling below all of the major moving averages (10–200-day). The Bollinger Bands have widened, reflecting elevated volatility, while XRP trades near the lower band around $2.29, acting as immediate support.

XRP daily chart. Credit: crypto.news
Momentum indicators remain mixed. The MACD and momentum continue to flash mild sell signals, and the relative strength index at 33.9 indicates near-oversold conditions. The commodity channel index, however, hints at a potential rebound if buying volume returns.

If bulls defend $2.30–$2.40, XRP could retest resistance around $2.75–$2.85, coinciding with the 20-day SMA. A break above this range could pave the way to $3.00–$3.20, particularly if ETF optimism increases. In contrast, if current support is not maintained, the 30-day downtrend may be extended with a retest of $2.00–$2.10.

BitMine added 104,336 ETH worth about $417m to its treasury through transactions linked to Kraken and BitGo, according to Lookonchain data.

A long-dormant Bitcoin wallet moved 2,000 BTC worth $222m to 51 new addresses, fueling speculation over whether whales are preparing to dump.

Follow up to the hour updates on what is happening in crypto today, October 16. Market movements, crypto news, and more!

The Bitcoin (BTC) price is showing signs of exhaustion after weeks of steady gains, hovering near $112,900 at the time of writing. Despite briefly testing highs above $115,900, the flagship crypto is struggling to maintain bullish momentum. Technical indicators now suggest a potential slowdown, as traders eye key support levels around $110,000. With market sentiment turning cautious, Bitcoin’s next move could determine whether it consolidates for another breakout or enters a short-term corrective phase.

The chart shared by analyst Ali highlights a striking similarity between Bitcoin’s current price structure and its 2021 market top. It shows that while Bitcoin’s price has been forming higher highs—currently peaking near $115,900—the Relative Strength Index (RSI) on the weekly timeframe has been printing lower highs, forming a clear bearish divergence. This indicates weakening buying momentum even as prices climb, often a precursor to a potential trend reversal or market correction.

The chart also outlines a curved resistance pattern, suggesting Bitcoin could be forming a “rounded top.” This structure typically appears when upward momentum starts fading and sellers begin to take control gradually. If Bitcoin fails to sustain above $110,000, the bearish divergence could play out, leading to a deeper pullback toward the $95,000–$100,000 range. Conversely, a breakout in RSI above its descending trendline could invalidate the bearish scenario, signaling renewed strength and opening the path toward $125,000 and beyond.

Wrapping it UpIn conclusion, the Bitcoin price appears to be approaching a critical inflection point, with technical indicators flashing early warning signs of a possible trend reversal. The bearish divergence between BTC’s price and RSI suggests fading momentum, similar to patterns seen before previous market corrections. While Bitcoin remains fundamentally strong, a short-term pullback toward the $95,000–$100,000 range cannot be ruled out. Traders should stay cautious around the $110,000 support, as the next move will likely determine whether BTC resumes its rally or enters a consolidation phase.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Coinbase Global Inc. (NASDAQ:COIN) added BNB (CRYPTO: BNB) to its listing roadmap on Wednesday as the native token of rival exchange Binance surges to record highs.

Subject To These ConditionsThe company said that the official launch of BNB is contingent on market-making support and required technical infrastructure.

"We will announce the launch of trading on X once these conditions are met," Coinbase stated. It warned that depositing the token before an official announcement may lead to loss of funds.

CZ Reacts To Coinbase’s ‘Hypocrisy’ Interestingly, just a few hours before the announcement, Binance co-founder Changpeng Zhao responded with a laughing emoji to an X post questioning Coinbase's perceived “hypocrisy” in failing to list BNB, one of the largest cryptocurrencies by market capitalization.

See Also: Binance Coin (BNB) Price Prediction: 2025, 2026, 2030

BNB’s Dream Run In 2025BNB is in the middle of a record-breaking bull run, with a new high of $1,370.55 clocked earlier this week. 

The asset, worth $5.8 billion, has rallied nearly 70% in 2025, far exceeding returns from Bitcoin (CRYPTO: BTC), Ethereum (CRYPTO: ETH), Solana (CRYPTO: SOL) and Dogecoin (CRYPTO: DOGE).

Binance remains the world’s largest cryptocurrency exchange, with 24-hour volumes exceeding $25 billion, according to CoinGecko. Coinbase, the largest cryptocurrency trading platform in the U.S., meanwhile, recorded volumes just over $3 billion in the same period.

Price Action: At the time of writing, BNB was exchanging hands at $1,187.09, down 1.63% in the last 24 hours, according to data from Benzinga Pro.

Coinbase shares rose 0.50% in after-hours trading after closing 1.54% lower at $336.30 during Wednesday’s regular trading session.

Benzinga’s proprietary Edge Rankings show Growth as the strongest category for the stock at 93.76/100. Visit Benzinga Edge Stock Rankings to compare it to other cryptocurrency-linked stocks.

Read Next: 

Strategy, MetaPlanet, BitMine Get Company: Here’s Who’s Building A Binance BNB Treasury
Photo Courtesy: T. Schneider on Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Cardano (ADA) edged higher to $0.70 (+2.2%) on Wednesday as on-chain data showed large holders buying the dip.

Whale and mid-tier wallets snapped up roughly 200 million ADA over 48 hours, about $140 million at recent prices, after last week’s volatility knocked the market lower. The build-up comes as the project readies the Cardano Summit in Berlin (Nov. 12–13), adding a fresh narrative tailwind into Q4.

ADA's price trends to the downside on the daily chart. Source: ADAUSD on Tradingview
Whales Scoop ADA as Selling Pressure Cools
Analytics platforms tracking address cohorts report renewed accumulation, with 10–100million ADA and over 1 billion ADA wallets expanding balances. Similarly, network “spent coin” metrics declined by 51%, suggesting fewer coins are moving to sell and that distribution is easing.

Price-wise, ADA continues to defend the $0.70–$0.80 band many traders view as pivotal for basing. A sustained hold keeps the recovery structure intact and positions the token for attempts at prior resistance.

Staking Access Expands, Berlin Summit In Focus
Adding fuel to the thesis, eToro launched ADA staking in the U.S., potentially opening rewards access to over 40 million users and reducing liquid supply as holders lock tokens.

Beyond flows, the community is eyeing the Berlin Summit, where ecosystem teams are expected to showcase progress across Midnight, Leios, and dApp growth, events that historically boost sentiment and developer visibility.

Strategists argue these catalysts, paired with bargain hunting from whales, can help stabilize spot liquidity after the broader market shake-out.

Cardano Price Outlook: Levels That Matter Now
Technically, Cardano rebounded from the $0.61 swing low and is attempting to reclaim short-term signals. Bulls first want a clean move through $0.73 (recent pivot / 0.236 Fib area).

Above that, chart watchers flag $0.86 as a major resistance repeatedly capping rallies; a breakout there exposes $1.01 and $1.12 as subsequent targets, aligning with an ascending-channel upper bound on higher time frames.

On the downside, $0.61 remains the must-hold support; a daily close below would risk a deeper revisit toward $0.50–$0.60 and delay any trend resumption. A decisive push through $0.73, and especially $0.86, would strengthen the case for a broader recovery leg, while failure to hold $0.61 puts ADA back in consolidation.

Cover image from ChatGPT, ADAUSD chart from Tradingview

BNB, the native token of the Binance ecosystem, has reached a new milestone, with its market capitalization climbing to approximately $165 billion. This achievement marks one of the most notable performances among large-cap cryptocurrencies in recent months and underscores the growing influence and resilience of the token in the broader crypto market.

Dogecoin struggled to rise above $0.2180 and corrected some gains against the US Dollar. DOGE is now consolidating and might decline below $0.1920.

DOGE price started a fresh downside correction below $0.2050.
The price is trading below the $0.240 level and the 100-hourly simple moving average.
There is a bearish trend line forming with resistance at $0.2025 on the hourly chart of the DOGE/USD pair (data source from Kraken).
The price could aim for a fresh increase if it remains stable above $0.1880.

Dogecoin Price Dips Again
Dogecoin price started a fresh increase after it settled above $0.20, like Bitcoin and Ethereum. DOGE climbed above the $0.2050 resistance to enter a positive zone.

The bulls were able to push the price above $0.2120 and $0.2150. A high was formed at $0.2182 and the price is now correcting gains. There was a move below the 50% Fib retracement level of the upward move from the $0.1788 swing low to the $0.2182 high.

Dogecoin price is now trading below the $0.2050 level and the 100-hourly simple moving average. Besides, there is a bearish trend line forming with resistance at $0.2025 on the hourly chart of the DOGE/USD pair.

Source: DOGEUSD on TradingView.com
If there is another increase, immediate resistance on the upside is near the $0.2025 level. The first major resistance for the bulls could be near the $0.2085 level. The next major resistance is near the $0.2120 level. A close above the $0.2120 resistance might send the price toward $0.2180. Any more gains might send the price toward $0.2250. The next major stop for the bulls might be $0.2320.

More Losses In DOGE?
If DOGE’s price fails to climb above the $0.2085 level, it could start a downside correction. Initial support on the downside is near the $0.1930 level and the 61.8% Fib retracement level of the upward move from the $0.1788 swing low to the $0.2182 high. The next major support is near the $0.1880 level.

The main support sits at $0.1800. If there is a downside break below the $0.1800 support, the price could decline further. In the stated case, the price might slide toward the $0.1665 level or even $0.1650 in the near term.

Technical Indicators

Hourly MACD – The MACD for DOGE/USD is now gaining momentum in the bearish zone.

Hourly RSI (Relative Strength Index) – The RSI for DOGE/USD is now below the 50 level.

Major Support Levels – $0.1930 and $0.1880.

Major Resistance Levels – $0.2085 and $0.2180.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Shiba Inu has restored BONE transfers on Shibarium’s Plasma bridge, re-enabling deposits and withdrawals between Ethereum and the layer-2 network following a security incident that forced a month-long pause. In an October 14 post, core contributor Kaal Dhairya wrote that the “Plasma Bridge is back online for BONE, following a comprehensive review and a series of security enhancements,” adding that users can now bridge BONE “with a safer, stronger, and more resilient experience.”

Shiba Inu Relaunches The Shibarium Bridge
The relaunch comes after Shibarium’s bridge was restricted in mid-September following a validator-key compromise that enabled a malicious exit on the PoS bridge. In a September 21 incident report, Dhairya stated that “on September 12, 2025 at 18:44 UTC, unauthorized validator signing power was used to push a malicious state/exit through the PoS bridge, withdrawing multiple assets,” prompting immediate containment measures and a broader hardening program. The team said at the time it would publish full technical details once it was safe to do so and that “bridging remains restricted during containment/hardening.”

Shibarium’s team is positioning the re-opened BONE bridge as the first step in a phased restoration of services, backed by new policy-level and operational controls. The most visible change for users is a mandatory delay before withdrawals finalize: “All BONE Plasma withdrawals now include a 7-day finalization delay. This buffer gives operators and security teams time to monitor and respond to unusual activity before funds finalize—significantly improving defense without removing user access.” The post frames the delay as reinforcing Plasma’s fraud-resistance guarantees.

Another control introduced at the bridge layer is proactive address blacklisting. According to the team, the new mechanism “lets us flag and block suspicious addresses at the bridge layer,” with the intent of preventing repeat abuse across the ecosystem. The Shiba Inu team also emphasized that critical code changes underwent an external review: “All critical changes were reviewed by Hexens, adding an independent layer of expert scrutiny.” The relaunch followed a validation sequence that included unit tests, end-to-end simulations, deployment on the public testnet (“Puppynet”), and “multi-timeframe” monitoring before production activation.

The October 14 update also addresses a separate strand of the September incident involving KNINE and minor OSCAR token flows. The Shiba Inu team disclosed that the attacker “drained and sold roughly $600 worth of OSCAR tokens from the bridge but ignored the 5 ETH recovery offer for KNINE tokens,” which now remain blacklisted and unusable to the attacker. The previously announced KNINE bounty “has expired,” the team said, but it plans “one final, conditional bounty (amount TBD) for complete return of all KNINE held by attacker-controlled addresses,” stressing that partial returns will not qualify and that terms will appear only on verified channels.

While only BONE is live on the Plasma bridge today, Shibarium signaled a broader roadmap. The team plans “gradual re-enablement for other tokens” and is “finalizing a fair and transparent repayment framework for affected users,” with specifics to be published once doing so would not increase risk. The post underscores a measured posture after the September compromise: “Safety first: We won’t publish specifics that could be gamed while security work is ongoing. Expect measured, verifiable updates.”

Context around the month-long outage highlights the extent of remediation behind the scenes. In late September, Shibarium detailed rotations of validator signers, migrations of contract control to multi-party hardware custody, targeted contract-level protections, live monitoring and exchange coordination, and the engagement of independent security and incident-response specialists. The September 21 update also acknowledged decentralization shortcomings in validator operations and outlined a hardening plan “in progress collaboration with Hexens,” with restoration gated on third-party sign-offs and successful drills on test environments.

For now, the reopening restores a critical path for validators, liquidity providers and users who rely on BONE mobility between Ethereum and Shibarium. As the post concludes, the new safeguards—including blacklisting and the 7-day challenge window—are intended to align the bridge’s user experience with the practical realities of operating a Plasma-style system under adversarial conditions: “Every new safeguard, every extra check, and yes—even the 7-day delay—reflects one core principle: protecting the community.”

At press time, the Shiba Inu (SHIB) token traded at $0.00001060.

Shiba Inu trades at key support zone, 1-week chart | Source: SHIBUSDT on TradingView.com
Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

The world’s largest Ether digital asset treasury, BitMine, has reportedly bought the dip again as ETH continues to retreat from its August all-time high.

Tom Lee-chaired BitMine Immersion Technologies reportedly scooped up a further 104,336 Ether (ETH) worth around $417 million on Thursday, according to onchain data.

Over the past seven hours, three new wallets received the assets from Kraken and BitGo, reported Lookonchain. BitMine has not publicly confirmed the transactions.

“Despite the crypto market crash, Tom Lee still predicts ETH will hit $10,000 by year-end,” they added.

Earlier this week, Lee and BitMEX co-founder Arthur Hayes doubled down on their prediction that Ether will hit $10,000 this year.

Blockchain intelligence firm Arkham agreed with the findings, stating that three new whale wallets just acquired $75 million in ETH each. “The acquisition patterns match BitMine ETH acquisitions from BitGo,” they said. 

BitMine bought the dip earlier this week following the weekend crypto market rout. On Monday, the firm announced that it acquired 202,037 ETH tokens “over the past few days,” taking advantage of the lower prices.  

“The crypto liquidation over the past few days created a price decline in ETH, which BitMine took advantage of,” said Tom Lee at the time. 

BitMine associated Ether transactions. Source: Arkham
DATs remain unfazed Digital asset treasuries, such as BitMine, appear to be unfazed by the recent crypto market turmoil, using the opportunity to buy the dips. 

BitMine has now reached 50% of its treasury target in just a few months, having accumulated a whopping 3 million ETH, equivalent to 2.5% of the entire supply. 

Its holdings also represent half of the Ether accumulated by all public corporate treasuries, which currently stands at 5.9 million ETH, worth $23.7 billion, according to StrategicEthReserve.

ETH down trend deepens The dip buying comes as Ether markets continue to trend downward. 

ETH fell to $3,945 in late trading on Wednesday, representing a 20% decline from its August all-time high of $4,946.  

It had regained a little composure at the time of writing, trading just above the psychological $4,000 level.

Mirroring chart patterns However, Tom Lee is among many experts and analysts who are confident that Ether will resume its bull run over the next couple of months.

“Ethereum is copying Bitcoin’s 2020-2021 run,” said analyst ‘Rekt Fencer’ before adding “$15,000 for ETH is still on the table this cycle.”

Meanwhile, market analyst ‘Crypto Bullet’ compared chart patterns from Bitcoin (BTC) in 2024 to Ether in 2025, stating that they are “exactly the same pattern,” before predicting an Ether move up to $6,000 to $7,000 this year.

ETH price action looks uncannily similar to Bitcoin’s last year: Source Crypto BulletMagazine: Ethereum’s roadmap to 10,000 TPS using ZK tech: Dummies’ guide

Bitcoin trades near a crucial support between $108,400 and $117,100, a zone that has historically prevented deeper corrections.Long-term holders have sold 300,000 BTC since July 2025, adding sustained sell pressure and limiting upside momentum.Holding above $110,000 could spark a rebound to $112,500, but a drop below $108,000 may trigger structural weakness and extended correction.Bitcoin is currently facing one of its most critical tests in months as its price hovers near a key support level that has repeatedly prevented deeper declines. 

However, investor sentiment and market conditions will now determine whether Bitcoin can sustain this level or risk entering a prolonged correction phase.

Bitcoin Is VulnerableBitcoin’s supply quantiles show that the asset has entered its third instance since late August, where spot prices dipped below the 0.95-quantile price model ($117,100). This level represents holdings where roughly 5% of supply, primarily owned by top buyers, sits at a loss. BTC currently trades within the 0.85–0.95 quantile range ($108,400–$117,100), reflecting a significant retracement from the euphoric phase of recent months.

Sponsored

Sponsored

Without renewed momentum to lift prices back above $117,100, Bitcoin risks sliding toward the lower boundary of this range. Historically, when BTC failed to sustain this critical support zone, extended mid- to long-term corrections followed. A drop below $108,000 would likely signal structural weakness, potentially leading to greater losses as investor confidence wavers.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Bitcoin Supply Quantiles. Source: GlassnodeThe broader macro environment remains challenging for Bitcoin. Since July 2025, persistent long-term holder (LTH) distribution has restricted upside potential. Data shows that approximately 0.3 million BTC have been offloaded by mature investors over this period, indicating steady profit-taking. This sustained sell-side pressure has limited demand growth and kept volatility elevated.

If the distribution trend continues without new inflows from institutions or retail buyers, Bitcoin could face further consolidation. Demand exhaustion may lead to localized capitulation events or temporary market pullbacks before long-term equilibrium returns. 

Bitcoin LTH Supply. Source: GlassnodeBTC Price Holds StrongBitcoin’s price has remained volatile since July 2025 due to macroeconomic pressure and shifting investor sentiment. Even so, BTC has repeatedly found stability around $110,000, signaling potential resilience.

The next major support lies at $108,000, a historically strong level that has been tested several times before. Holding above this zone could enable a rebound toward $112,500 in the short term, especially if macro conditions improve.

Bitcoin Price Analysis. Source: TradingView
However, if bearish pressure intensifies and selling accelerates, Bitcoin could fall below $110,000. A breakdown under $108,000 would invalidate the bullish-neutral outlook and expose BTC to deeper structural weakness.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Bitcoin may struggle to sustain its upward trend unless something triggers more excitement among investors, according to Glassnode.

“Without a renewed catalyst to lift prices back above $117.1k, the market risks deeper contraction toward the lower boundary of this range,” Glassnode said in a report published on Wednesday. 

Bitcoin (BTC) is trading at around 5% below the $117,000 level, trading at $110,840 at the time of publication, according to CoinMarketCap.

Bitcoin has declined by 4.19% over the past 30 days. Source: CoinMarketCap“Historically, when price fails to hold this zone, it has often preceded prolonged mid- to long-term corrections,” Glassnode said, pointing out the increase in profit-taking among long-term holders in recent times, which may signal “demand exhaustion.”

Hyblock Capital CEO Shubh Varma told Cointelegraph that he expects a “relatively volatile month,” with potential upside ranging from $116,000 to $120,000. 

Sideways price action is “likely outcome” after a crashHowever, Varma said that while “consolidation is the likely outcome” for Bitcoin following a significant market crash, several indicators still point to potential positive momentum for the cryptocurrency.

“ETFs inflows remain quite high, and spot volume seems healthy,” Hyblock said. Before the wider crypto market crash on Friday, which saw Bitcoin briefly fall to $102,000, US-based spot Bitcoin ETFs had recorded a 9-day inflow streak, amounting to $5.96 billion in inflows, according to Farside data.

Another potential bullish catalyst is the prospect of continued rate cuts from the US Federal Reserve. Rate cuts are typically viewed as bullish for riskier assets, such as cryptocurrencies, as they prompt investors to shift away from traditional investments like bonds and term deposits, which become less attractive in a lower interest rate environment.

According to the CME FedWatch Tool, markets are pricing in about a 95.7% chance of another rate cut at the Fed’s Oct. 29 meeting.

Other indicators suggest “increasingly constructive” rest of the year21Shares crypto research strategist Matt Mena said that with the recent liquidations, policy easing approaching, and structural demand accelerating, the setup into year-end appears “increasingly constructive for digital assets.”

Mena said Bitcoin is setting up for a potential move toward $150,000 “as macro tailwinds and institutional flows continue to align.”

Meanwhile, other analysts are predicting higher values by year-end. BitMEX co-founder Arthur Hayes and Unchained Market Research Director Joe Burnett are forecasting a price of $250,000 by the end of 2025.

Magazine: Sharplink exec shocked by level of BTC and ETH ETF hodling: Joseph Chalom

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

Inventive partnership transforms the live streaming experience, allowing viewers to purchase e.l.f. products directly through Twitch streams marking an eyes.lips.first.

OAKLAND, Calif.--(BUSINESS WIRE)--e.l.f. Cosmetics, a brand from e.l.f. Beauty (NYSE: ELF), today announced an innovative partnership with Twitch, powered by Amazon Ads, to become the first brand to run an all-new and native in-stream live-shopping element on the popular streaming service.

e.l.f. Cosmetics, a brand from e.l.f. Beauty (NYSE: ELF), today announced an innovative partnership with Twitch, powered by Amazon Ads, to become the first brand to run an all-new and native in-stream live-shopping element on the popular streaming service.

Share
Building on e.l.f.'s popularity with the Twitch community, this first-of-its-kind collaboration allows viewers to seamlessly purchase e.l.f. products directly through Twitch streams without interrupting their viewing experience. The eyes.lips.first. shoppable element will initially appear on e.l.f.'s official Twitch channel, e.l.f.YOU!

Designed to keep audiences engaged while driving measurable business outcomes, this innovative ad format allows brands to connect with highly-engaged communities, turning authentic creator moments into instant product discovery and conversion — all without disrupting the viewing experience.

“When we launched e.l.f.YOU! on Twitch, our vision was simple yet bold — to meet our community where they play, create and connect. Live Streaming on Twitch has always been about self-expression, and we saw an opportunity to ‘game-up’ the space by bringing beauty into the conversation and creating a safe space for every eye, lip and face,” said Patrick O'Keefe, Chief Integrated Marketing Communications Officer at e.l.f. Beauty. “From the start, e.l.f.YOU! was designed to empower female gamers, celebrate creativity and build confidence at the intersection of makeup and the streaming culture. We didn’t just want to show up on Twitch — we wanted to level it up, amplify voices that were often overlooked and prove that beauty belongs everywhere.”

“Twitch is where communities and creators connect through authentic, live engagement — and now, through shoppable moments," said Sarah Iooss, Head of US Agency, Amazon Ads. "We’re thrilled to partner with e.l.f. to test this innovative new format that keeps viewers immersed in the content they love while discovering and purchasing products in real time. It’s an exciting example of how Amazon Ads is helping brands meet customers in more natural, interactive, and joyful ways.”

e.l.f.’s Patrick O'Keefe will appear at TwitchCon San Diego 2025 on the panel “The Future of Co-Creation: Creator & Brand Team-Ups,” where he will discuss this innovative partnership. This event takes place from October 17-19, 2025, at the San Diego Convention Center.

Since launching its presence on Twitch in 2020, e.l.f. has built a vibrant community through engagement with gamers, beauty enthusiasts and creators. The brand's gaming initiatives have included custom tournaments, creator partnerships and limited-edition product collaborations that celebrate the intersection of gaming and beauty. e.l.f.YOU! on Twitch has become a top-performing channel: 43.3M+ Minutes Watched; 800k+ Chat Messages; 64,400+ Minutes Streamed on e.l.f.YOU!

About e.l.f. Cosmetics

e.l.f. Beauty (NYSE: ELF) is fueled by a belief that anything is e.l.f.ing possible. We are a different kind of company that disrupts norms, shapes culture and connects communities through positivity, inclusivity and accessibility. e.l.f. Cosmetics, our global flagship brand, makes the best of beauty accessible to every eye, lip and face by bringing together the best of beauty, culture and entertainment. Our superpower is delivering universally appealing, premium quality products at accessible prices that are e.l.f. clean and vegan, all double-certified by Leaping Bunny and PETA as cruelty free. We are proud to have products made in Fair Trade Certified™ facilities. Learn more at www.elfcosmetics.com.

More News From e.l.f. Cosmetics

Back to Newsroom

Secures UL and cUL certifications for four types of low- and medium-voltage circuit breakers, reinforcing competitiveness in North America
Global low- and medium-voltage circuit breaker market projected to reach USD 29.2 billion by 2034, growing at a CAGR of 8.8%
"The company plans to expand its presence beyond high-voltage transformers to include low- and medium-voltage circuit breakers in North America."
, /PRNewswire/ -- HD Hyundai Electric has secured UL certification, establishing a foothold to expand its market share in North America's low- and medium-voltage circuit breaker market.

Four models of HD Hyundai Electric’s low- and medium-voltage circuit breakers certified with UL and cUL

HD Hyundai Electric announced on Tuesday, October 14, that four types of its low- and medium-voltage circuit breakers — air circuit breakers (ACB), molded case circuit breakers (MCCB), vacuum circuit breakers (VCB), and magnetic contactors (MC) — have obtained UL (Underwriters Laboratories) and cUL (Canadian UL) certifications, the leading safety standards in the North American market.

The UL certification is a globally recognized mark of safety and quality granted by Underwriters Laboratories, a prominent U.S.-based safety certification organization, following rigorous testing and evaluation of electrical, electronic, and industrial equipment. Although not legally mandatory, UL and cUL certifications are effectively required for electrical products distributed in North America, particularly those with potential safety risks such as fire or electric shock. As such, they play a critical role in ensuring product reliability and enhancing market competitiveness.

Low- and medium-voltage circuit breakers are essential components in power distribution systems, delivering electricity generated at power plants to end users. They ensure stable power supply and protect facilities by interrupting excessive current flow during overloads. Depending on voltage levels, they are widely used across residential, commercial, and industrial applications — representing a large and resilient market closely tied to everyday life.

According to Global Market Insights, the global low- and medium-voltage circuit breaker market is projected to grow from USD 12.2 billion in 2024 to nearly USD 29.2 billion by 2034, representing a compound annual growth rate (CAGR) of 8.8% — a 2.4-fold increase over the decade.

An HD Hyundai Electric official said, "With the acquisition of UL certification, we plan to expand our presence beyond high-voltage transformers — where we have consistently held the top market share in North America — into the broader power distribution equipment sector, including low- and medium-voltage circuit breakers."

Meanwhile, HD Hyundai Electric plans to complete the construction of a new power distribution equipment plant in Cheongju, Korea, by the end of this year, further supporting its expansion in the low- and medium-voltage segment. The new Cheongju plant will feature an advanced smart factory system designed to maximize manufacturing efficiency. Once completed, the facility is expected to double the company's annual production capacity of low- and medium-voltage circuit breakers to approximately 13 million units.

SOURCE HD Hyundai

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read platforms.Leveraging Roche’s SBX technology, Broad Clinical Labs achieved the new GUINNESS WORLD RECORD™ for fastest DNA sequencing technique in under four hours, in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital.Wellcome Sanger Institute joins a growing network of early collaborators using SBX technology, driving new insights in genomics research. Basel, 16 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented major updates on its innovative sequencing by expansion (SBX) technology at the American Society of Human Genetics (ASHG) 2025 Annual Meeting in Boston, USA. Following its recent unveiling, SBX is already being recognized by early evaluators in the sequencing community for its combination of speed, flexibility, and longer reads, which significantly expands research possibilities.

“These advances reflect the strong momentum behind our innovative sequencing technology and its potential to transform genomic research and clinical applications,” said Matt Sause, CEO of Roche Diagnostics. “By combining high throughput, speed and longer read lengths, the SBX technology has the potential to enable research and applications that were previously not feasible. Our collaborations with Broad Institute, the Wellcome Sanger Institute, and others, demonstrate the immense potential of the SBX technology to tackle some of biology’s biggest challenges.”

Breaking a GUINNESS WORLD RECORD™
The impact of the SBX technology was recognised when Broad Clinical Labs broke the GUINNESS WORLD RECORD™ for the fastest DNA sequencing technique to date, using a human genome processed from a DNA sample to a final variant call file (VCF) in less than four hours. This milestone, achieved in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital, surpasses the previous benchmark of five hours and two minutes.

“Breaking the GUINNESS WORLD RECORD is a remarkable achievement,” said Mark Kokoris, inventor of the SBX chemistry and Head of SBX Technology at Roche. “The true impact lies in what this speed and accuracy mean for the scientific community and for deciphering complex diseases like cancer and neurodegenerative conditions.”

Growing collaborations
At ASHG 2025, Roche also announced a new collaboration with the Wellcome Sanger Institute, marking the start of a multi-project evaluation of SBX’s capabilities across a range of research applications. The Wellcome Sanger Institute is evaluating potential benefits from longer reads and very high throughput from the SBX technology for instance in Bulk RNA sequencing to explore previously undetectable features such as certain spliced Isoforms.

The Wellcome Sanger Institute partnership adds to existing collaborations that includes Hartwig Medical Foundation, Genentech, The University of Tokyo and others, as well as the Broad Institute where we previously announced a strategic collaboration to develop and pilot groundbreaking research applications.

Methylation mapping with SBX-Duplex
Roche has also made significant progress in methylation mapping – the process of identifying and analysing chemical modifications called methyl groups that are added to DNA. These modifications act like switches or dimmers, controlling whether genes are turned on, off, or somewhere in between. The research workflow combines SBX-Duplex, a methodology in which both strands of the target DNA are linked in a single read, with a high-fidelity methylation mapping method, TET-assisted pyridine borane sequencing (TAPS), a technology in development by Watchmaker Genomics.

This high efficiency intra-molecular consensus workflow can have significant advantages in research applications, including liquid biopsy-based cancer detection and identification of novel epigenetic biomarkers.

Spatial sequencing
At the University of Tokyo, researchers working in collaboration with Roche leveraged the speed and workflow adaptability of SBX in spatial sequencing analyses of banked lung cancer tissue with about 15 billion reads in just one hour. This approach allowed them to rapidly and accurately map gene expression within tissue samples at high resolution, providing critical insights into the dynamics of cells within a tumor microenvironment.

Target enrichment
Roche also demonstrated a target enrichment method using SBX-Simplex workflow that leverages Unique Molecular Identifiers (UMIs) to produce high throughput and high accuracy reads with very low inputs. This can potentially benefit Oncology research where high depth is typically required.

The above examples highlight SBX’s potential to support multiomics research at scale, by combining the power of rapid sequencing with the ability to analyse multiple layers of biological information. Such breakthroughs are redefining how researchers approach disease biology and interpret the interplay between genetics, transcriptional activity, and epigenomic changes.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] The SBX technology and analysis tools are in development and not commercially available. The content of this material reflects current study results or design goals.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58 Sileia Urech
Phone: +41 79 935 81 48 Nathalie Altermatt
Phone: +41 79 771 05 25 Lorena Corfas
Phone: +41 79 568 24 95 Simon Goldsborough
Phone: +44 797 32 72 915 Karsten Kleine
Phone: +41 79 461 86 83 Kirti Pandey
Phone: +49 172 6367262 Yvette Petillon
Phone: +41 79 961 92 50 Dr Rebekka Schnell
Phone: +41 79 205 27 03   Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]   Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]  

Media & Investor Release ASHG SBX World Record English

OMAHA, Neb.--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced a strategic partnership with BitPay, the world’s leading cryptocurrency payments processor, to further expand its digital assets solutions for merchants and payment service providers (PSPs) through ACI's Payments Orchestration Platform.

Our partnership with BitPay represents one element of our broader digital assets strategy. Based on growing demand from our PSPs and merchant clients, we're ensuring they have multiple pathways to leverage these emerging rails where they add value.

Share
This partnership strengthens ACI’s commitment to digital currency innovation by expanding the platform’s established capabilities for merchants and PSPs. According to a recent study by ACI Worldwide and Payments Dive, 55% of global retailers are evaluating cryptocurrency acceptance as part of their payment strategy.

By integrating BitPay, ACI further differentiates its Payments Orchestration Platform, enabling seamless acceptance and management of digital currencies including stablecoins as a strategic complement to traditional payment rails. Building on capabilities ACI introduced in 2021, merchants and PSPs can now integrate BitPay, alongside other payment options to access upgraded features - including the ability to accept, store, and spend cryptocurrencies. BitPay's platform supports a range of use cases, including peer-to-peer payments, and mobile point-of-sale applications.

"As regulated stablecoins evolve from niche to mainstream, they're creating new opportunities for cross-border transactions and settlement optimization," said Adriana Iordan, Global Head of Merchant at ACI Worldwide. "Our partnership with BitPay represents one element of our broader digital assets strategy. Based on growing demand from our PSPs and merchant clients, we're ensuring they have multiple pathways to leverage these emerging rails where they add value - whether for payment acceptance or specific use cases like cross-border B2B settlements and treasury operations."

"Together with ACI Worldwide, we're making digital currencies more accessible and practical for real-world commerce," said Stephen Pair, Co-Founder and CEO at BitPay. "This partnership brings our proven crypto payment capabilities to ACI's global customer base, enabling everything from simple payment acceptance to cross-border settlement scenarios as market demand develops."

The integrated solution supports settlement in both fiat and stablecoins, offering enhanced flexibility and efficiency for merchants operating in diverse markets. As our clients explore these capabilities, businesses can leverage stablecoins for treasury operations, supplier payments, and cross-border settlements - creating new options for how global commerce can operate.

ACI's Payment Orchestration Platform streamlines the complexity of managing multiple payment methods, acquirers, and gateways through a single, unified interface. By incorporating various digital currency solutions, merchants and PSPs can explore new revenue opportunities - typically seeing a 1–3% percent growth in sales where implemented - while offering customers greater choice and convenience at checkout.

“ACI Worldwide remains committed to a rail-agnostic approach, expanding its digital assets ecosystem through additional partnerships and integrations as the market matures,” continued Adriana Iordan. “This ensures our clients are prepared to leverage digital payment innovations as use cases emerge and regulatory frameworks solidify.”

About ACI Worldwide

ACI Worldwide, an original innovator in global payments technology, delivers transformative software solutions that power intelligent payments orchestration in real time so banks, billers, and merchants can drive growth, while continuously modernizing their payment infrastructures, simply and securely. With 50 years of trusted payments expertise, we combine our global footprint with a local presence to offer enhanced payment experiences to stay ahead of constantly changing payment challenges and opportunities.

About BitPay

Founded in 2011, BitPay is one of the oldest cryptocurrency companies. As a pioneer in blockchain payment processing, the company's mission is to transform how businesses and people send, receive, and store money. Its business solutions eliminate fraud chargebacks, reduce the cost of payment processing, and enable borderless payments in cryptocurrency, among other services. For consumers, the BitPay Wallet offers a complete digital asset management solution to buy, store, swap, sell, and spend cryptocurrency with ease. The company has offices in North America, Europe, and South America and has raised more than $70 million in funding from leading investment firms including Founders Fund, Index Ventures, Virgin Group, and Aquiline Technology Growth. For more information visit bitpay.com.

© Copyright ACI Worldwide, Inc. 2025

ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties’ trademarks referenced are the property of their respective owners.

The logo of German pharmaceuticals company Merck is seen at the company's headquarters in Darmstadt, Germany, May 16, 2016. REUTERS/Kai Pfaffenbach/File Photo Purchase Licensing Rights, opens new tab

Oct 16 (Reuters) - German pharmaceuticals and technology company Merck KGaA

(MRCG.DE), opens new tab slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.

Merck now expects mid-term annual organic sales growth in the low- to mid single-digit percentage range for its healthcare business, having guided for "slight growth" last year. It expects mid-to-high single-digit percentage growth for Life Science, after guiding for 7% to 9% last year.

Sign up here.

The company also confirmed that it is aiming to achieve net sales between around 20.5 to 21.7 billion euros in 2025, a target it has cut twice this year.

This is far below the 25 billion euros the Darmstadt-based firm had previously guided for at its capital markets day in 2021.

"We had made a number of assumptions on the pandemic that never materialized," Merck's Chief Executive Belen Garijo said in an interview.

The company's life science business was affected by a "Covid cliff" where mRNA vaccines were not in demand for as long as expected, she said.

Reporting by Marleen Kaesebier, Patricia Weiss and Matthias Inverardi; editing by Matt Scuffham

Our Standards: The Thomson Reuters Trust Principles., opens new tab

SummaryChipotle aims to expand from 3,750 to over 7,000 North American locations and is pursuing international growth despite uncertain global demand for Mexican cuisine.CMG is improving operational efficiency with new staff roles and kitchen technology, enhancing customer service speed and employee retention.The company is piloting catering services, which could significantly boost profitability if scaled successfully without disrupting core operations.Risks include weaker lower-income consumer spending and potential stock market declines, which could impact CMG's sales and valuation. Anne Czichos/iStock Editorial via Getty Images

Introduction: Chipotle (NYSE:CMG) is an incredibly popular fast-casual restaurant chain that has taken the United States by storm over the past couple of years. I believe that, despite some near term headwinds such as

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CMG over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1

eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 

Fabhalta is first and only approved complement inhibitor for adults with IgAN and has potential to delay disease progression4,5 

Fabhalta received accelerated approval for reduction of proteinuria in adults with IgAN in US in 2024; data support 2026 submission for traditional FDA approval4,5  Basel, October 16, 2025 – Novartis today announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta® (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta, an oral alternative complement pathway inhibitor, demonstrated statistically significant, clinically meaningful superiority compared to placebo in slowing IgAN progression measured by annualized total slope of estimated glomerular filtration rate (eGFR) decline over two years1.  

“Progressive diseases such as IgAN present an urgent need for interventions that can ultimately improve kidney health. Many people with IgAN commonly experience fear and anxiety of disease progression,” said Ruchira Glaser, Development Unit Head, Cardiovascular, Renal & Metabolic, Novartis. “We are excited about today’s positive Phase III APPLAUSE-IgAN results showing slowed eGFR decline, which add to the growing evidence of Fabhalta as a targeted therapy to preserve long-term kidney function, giving hope to people living with this condition.” 

Novartis intends to use these data to support Fabhalta submissions in 2026. Alongside Fabhalta, Novartis continues to advance its multi-asset IgAN portfolio, which also includes Vanrafia® (atrasentan) and investigational compound zigakibart.

IgAN is a progressive autoimmune kidney disease with approximately 25 per million people newly diagnosed worldwide each year3. IgAN is highly debilitating as it leads to glomerular inflammation, proteinuria, and a gradual decline in eGFR2. Up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis or kidney transplantation as part of long-term disease management2,6,7. Furthermore, people living with IgAN often face mental, social, and economic challenges2,8. Supportive care does not address the underlying causes of the disease and often fails to slow disease progression, reinforcing the need for more targeted therapies for IgAN3,9.

In APPLAUSE-IgAN, Fabhalta was well tolerated with a favorable safety profile in line with previously reported data10. Full data from the APPLAUSE-IgAN final analysis will be presented at future medical meetings.

About Fabhalta® (iptacopan) 
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway10.

Discovered at Novartis, Fabhalta received US Food and Drug Administration (FDA) and European Commission (EC) approval in December 2023 and May 2024, respectively, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta also received accelerated approval in the US in August 2024, and in China in September 2025, for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression (generally UPCR ≥1.5 g/g4,5,11,12. In 2025, Fabhalta received FDA and EC approval as well as approvals in China and Japan for the treatment of adults with C3 glomerulopathy (C3G), making it the first treatment approved for this condition13-15. 

Fabhalta is being studied in a broad range of rare kidney diseases, including atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN) and lupus nephritis (LN)16-18. Studies are ongoing to evaluate the safety and efficacy profiles in these investigational indications and support potential regulatory submissions16-18. 

About APPLAUSE-IgAN 
APPLAUSE-IgAN (NCT04578834) is a Phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of twice-daily oral Fabhalta (200 mg) in 477 adult primary IgAN patients (main study population). Patients were randomized to Fabhalta or placebo, on top of supportive care (a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of SGLT2i)1.    

The two primary endpoints of the study for the interim and final analysis, respectively, are proteinuria reduction at 9 months as measured by UPCR, and the annualized total eGFR slope over 24 months10,18. During the final analysis, the following secondary endpoints were assessed: proportion of participants reaching UPCR <1 g/g without receiving corticosteroids/immunosuppressants or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating kidney replacement therapy (KRT), time from randomization to first occurrence of composite kidney failure endpoint event (reaching either sustained ≥30% decline in eGFR relative to baseline or sustained eGFR <15 mL/min/1.73 m2 or maintenance dialysis or receipt of kidney transplant or death from kidney failure), and change from baseline to 9 months in the fatigue scale measured by the Functional Assessment Of Chronic Illness Therapy-Fatigue questionnaire19.    

The main study population enrolled patients with an eGFR ≥30 mL/min/1.73 m2 and UPCR ≥1 g/g at baseline10,18. In addition, a smaller cohort of patients with severe renal impairment (eGFR 20–30 mL/min/1.73 m2 at baseline) was also enrolled to provide additional information but not contributing to the main efficacy analyses10,19. 
    
Novartis commitment to kidney diseases 
Building on a 40-year legacy that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need.  

Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms - whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis and get patients the right care, sooner.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

Novartis. Data on file. Kwon CS, Daniele P, Forsythe A et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. J Health Econ Outcomes Res 2021;8:36–45. Cheung C, Barratt J. The rapidly changing treatment landscape of IgA nephropathy. Semin Nephrol 2025;44:151573. Novartis Pharmaceuticals Corporation. Fabhalta prescribing information. 2023 (2025 update). Available at: https://www.novartis.com/us-en/sites/novartis_us/files/fabhalta.pdf (accessed October 2025). Novartis Pharmaceuticals Corporation. Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) (2024). Available at: https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan (accessed October 2025). Pitcher D, Braddon F, Hendry B et al. Long-term outcomes in IgAN. Clin J Am Soc Nephrol 2023;18:727–8.Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Long-term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. PLoS One. 2021;16:e0249592. National Kidney Foundation. The voice of the patient (2020). Available at: https://igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf (accessed October 2025).Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1–276. Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392:531–543.Fabhalta®. EMA Summary of Product Characteristics. Novartis Europharm Limited (2024). Available at: https://www.ema.europa.eu/en/documents/product-information/fabhalta-epar-product-information_en.pdf (accessed October 2025). PHARMCUBE. Novartis expands indications for iptacopan, capmatinib in China (2025). Available at: Novartis Expands Indications for Iptacopan, Capmatinib in China PharmCube-News & Reports (accessed October 2025). Fineline Cube. Novartis’ fabhalta approved in China for C3 glomerulopathy (2025). Available at: Novartis' Fabhalta Approved in China for C3 Glomerulopathy - Insight, China's Pharmaceutical Industry (accessed October 2025). Pharma Japan. Novartis makes full foray into nephrology space with fabhalta: exec (2025). Available at: Novartis Makes Full Foray into Nephrology Space with Fabhalta: Exec | PHARMA JAPAN (accessed October 2025).Novartis. Press release. Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) (2025). Available at: https://www.novartis.com/news/media-releases/novartis-receives-third-fda-approval-oral-fabhalta-iptacopan-first-and-only-treatment-approved-c3-glomerulopathy-c3g (accessed October 2025). Clinicaltrials.gov. NCT04889430. Efficacy and Safety of Iptacopan (LNP023) in Adult Patients with Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS). Available at: https://clinicaltrials.gov/study/NCT04889430 (accessed October 2025).  Clinicaltrials.gov. NCT05755386. Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT). Available at: https://clinicaltrials.gov/study/NCT05755386 (accessed October 2025). Clinicaltrials.gov. NCT05268289. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/ - V. Available at: https://clinicaltrials.gov/study/NCT05268289 (accessed October 2025). Rizk DV, Rovin BH, Zhang H et al. Targeting the alternative complement pathway with iptacopan to treat IgAN: design and rationale of the APPLAUSE-IgAN study. Kidney Int Rep 2023;8:968–79.  # # #

SummaryI believe Palantir's UK strategic partnership should catalyze international government growth from future NATO and European MoD wins.Considering the momentum in the number of deals announced since PLTR's last earnings season (7 at the moment of writing this article), I see a high-probability Q3 and FY25 beat.Despite robust US commercial growth, international commercial revenue remains weak, hindered by EU AI regulations and a lack of new deals.I am now ultra-bullish on PLTR, expecting the company to outperform Street estimates in Q3 and maintain its upward trajectory. merc67/iStock via Getty Images

In my last coverage on Palantir Technologies Inc. (NASDAQ:PLTR) (NEOE:PLTR:CA), I was quite cautious with my bull thesis, given that I estimated that 76% of cRPO depends on cancelable sub-12-month contracts.

Since then, I've been keeping

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Elon Musk’s one-word reply on X has put Bitcoin back in the headlines, even if the comment was brief. His simple response — “True” — came after a widely shared post linking recent gains in gold, silver and Bitcoin to heavy government spending and currency debasement. Markets and crypto fans noticed fast.

Musk’s Brief Reply Signals Interest
According to the post by ZeroHedge, which has more than 2 million followers, the rallies were tied to what the author called an AI “arms race” between the US and China and to large-scale fiscal outlays.

Musk agreed with the thread. He added a view that echoes a common pro-Bitcoin line: fiat can be printed, while Bitcoin’s tie to energy gives it a different kind of backing. That single-word answer reopened a conversation many thought had cooled.

The money is not the problem: AI is the new global arms race, and capex will eventually be funded by governments (US and China). If you want to know why gold/silver/bitcoin is soaring, it’s the “debasement” to fund the AI arms race.

But you can’t print energy https://t.co/qwdD8QbVON

— zerohedge (@zerohedge) October 14, 2025

True.

That is why Bitcoin is based on energy: you can issue fake fiat currency, and every government in history has done so, but it is impossible to fake energy.

— Elon Musk (@elonmusk) October 14, 2025

Tesla’s Past Moves And Holdings
Based on reports, Tesla bought $1.5 billion of Bitcoin in early 2021 and said it would take the coin as payment for cars. But the deal was short-lived.

The company soon stopped accepting Bitcoin because of concerns about mining’s heavy energy use and said it might resume payments only after a major move toward renewable mining practices.

By mid-2022, Tesla sold about 75% of its holdings, a move that happened near a market low and drew wide notice. According to Arkham Intelligence, Tesla still holds roughly 11,509 BTC, which is worth about $1.25 billion at current prices.

BTCUSD now trading at $111,517, Chart: TradingView
What The Market Might Be Watching
Traders read signals. A single public endorsement from a high-profile executive used to move prices more. That was the case in 2021 when Tesla’s investment and payment plan helped lift sentiment.

Now, the context is different. Crypto markets are bigger and more diverse, and a one-word message does not equal a corporate decision. No official change at Tesla has been reported, and company spokespeople have not confirmed any shift in strategy.

Featured image from ET Edge Insights, chart from TradingView